() has announced the launch of hVIVO’s COVID Clear Test, its antibody testing service, following the successful completion of installation, testing and training for the coronavirus (COVID-19) test, The service will be offered to large employer groups and partners including GP networks, nursing care businesses, health clinics and private hospitals. Samples will be tested in the company’s London lab with results returned within 48 hours.
() said it has signed a five-year deal with Abu Dhabi Motorsport Management (ADMM) to design, develop and deliver an esports racing championship (ERC). The AIM-listed firm said the ERC concept is based on a “unique format not seen in virtual racing before” and will feature professional simulation racing drivers and a roster of teams from digital motorsport. The championship will have two seasons each calendar year, with the first to take place in 2020 and be hosted by Gfinity.
() has received a takeover bid from Canadian-listed cannabinoid (CBD) extraction and agriculture specialist Stillcanna Inc. The offer, which was unveiled after Wednesday’s London close, will see Stillcanna offer 0.33507 new shares for each Sativa share, valuing the Aquis Exchange-listed company’s entire share capital at around £10.66mln. The offer represents a 28.6% discount to Sativa’s middle market closing price of 2.6p per share on April 21, when a deal was first mooted, and the group noted that following the deal its shareholders will own around 65% of the combined entity. In a separate announcement, also after yesterday’s close, Sativa reported its results for the year ended December 31, 2019, which saw its revenues increase more than five-fold to £1.45mln from £0.26mln while its gross margins improved to 52% from 42% due to a decrease in the cost of CBD extract and production efficiencies. Sativa also reported figures for the first quarter of 2020, posting revenues of £0.36mln, 49% higher than the prior-year and gross profit of £0.21mln with a 59% margin, ahead of management expectations.
Holdings PLC () said it is expecting further strong growth in the top-line in the current fiscal year. In a trading update covering the 12 months to the end of May 2020, the immunodiagnostics specialist noted that its revenue was in line with market expectations. Meanwhile, it said, the next 18 months are expected to create substantial revenues within the EarlyCDT lung cancer test business. while the pipeline of contracts within the ImmunoINSIGHTS services business is building. also noted that its board has been streamlined, as a result of which Geoffrey Hamilton-Fairley, the non-executive vice-chairman and co-founder of the company, plus two other non-executive directors – Julian Hirst and Carsten Schroeder – have stepped down from the board with immediate effect.
() () said the chairman of its scientific advisory board has received a research grant from the National Institutes of Health in the US to investigate…
Read More: Open Orphan PLC, Gfinity PLC, Sativa Group PLC, Oncimmune PLC …